[en] Rheumatoid arthritis (RA) is an autoimmune disease with an important inflammatory component accompanied by deregulated redox-dependent signaling pathways that are feeding back into inflammation. In this context, we bring into focus the transcription factor NRF2, a master redox regulator that exerts exquisite antioxidant and anti-inflammatory effects. The review does not intend to be exhaustive, but to point out arguments sustaining the rationale for applying an NRF2-directed co-treatment in RA as well as its potential limitations. The involvement of NRF2 in RA is emphasized through an analysis of publicly available transcriptomic data on NRF2 target genes and the findings from NRF2-knockout mice. The impact of NRF2 on concurrent pathologic mechanisms in RA is explained by its crosstalk with major redox-sensitive inflammatory and cell death-related pathways, in the context of the increased survival of pathologic cells in RA. The proposed adjunctive therapy targeted to NRF2 is further sustained by the existence of promising NRF2 activators that are in various stages of drug development. The interference of NRF2 with conventional anti-rheumatic therapies is discussed, including the cytoprotective effects of NRF2 for alleviating drug toxicity. From another perspective, the review presents how NRF2 activation would be decreasing the efficacy of synthetic anti-rheumatic drugs by increasing drug efflux. Future perspectives regarding pharmacologic NRF2 activation in RA are finally proposed.
Précision sur le type de document :
Compte rendu
Disciplines :
Biochimie, biophysique & biologie moléculaire
Auteur, co-auteur :
Manda, Gina; Radiobiology Laboratory, Victor Babes National Institute of Pathology, Bucharest, Romania
Milanesi, Elena; Radiobiology Laboratory, Victor Babes National Institute of Pathology, Bucharest, Romania
Genc, Sermin; Neurodegeneration and Neuroprotection Laboratory, Izmir Biomedicine and Genome Center, Izmir, Turkey, Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey, Department of Neuroscience, Health Science Institute, Dokuz Eylul University, Izmir, Turkey
Niculite, Cristina Mariana; Radiobiology Laboratory, Victor Babes National Institute of Pathology, Bucharest, Romania, Department of Cellular and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Neagoe, Ionela Victoria; Radiobiology Laboratory, Victor Babes National Institute of Pathology, Bucharest, Romania
TASTAN, Bora ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Neuroinflammation Group ; Neurodegeneration and Neuroprotection Laboratory, Izmir Biomedicine and Genome Center, Izmir, Turkey, Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey
Dragnea, Elena Mihaela; Radiobiology Laboratory, Victor Babes National Institute of Pathology, Bucharest, Romania
Cuadrado, Antonio ; Department of Biochemistry, Medical College, Autonomous University of Madrid (UAM), Madrid, Spain, Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain, Instituto de Investigación Sanitaria La Paz (IdiPaz), Madrid, Spain, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. Electronic address: antonio.cuadrado@uam.es
Co-auteurs externes :
yes
Langue du document :
Anglais
Titre :
Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis.
The collaboration of the authors was supported by European COST Action CA20121 : Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (BenBedPhar). Webpage: https://benbedphar.org/about-benbedphar/ . GM, EM, CMN, IVN, EMD and AC were supported by the Romanian Ministry of Research, Innovation and Digitization through the European Regional Development Fund, Competitiveness Operational Program 2014–2020 [the REDBRAIN project, ID: P_37_732]. The authors thank to Dr. Andrei Constantinescu for revising the English language in the manuscript.The collaboration of the authors was supported by European COST Action CA20121: Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (BenBedPhar). Webpage: https://benbedphar.org/about-benbedphar/. GM, EM, CMN, IVN, EMD and AC were supported by the Romanian Ministry of Research, Innovation and Digitization through the European Regional Development Fund, Competitiveness Operational Program 2014–2020 [the REDBRAIN project, ID: P_37_732]. The authors thank to Dr. Andrei Constantinescu for revising the English language in the manuscript.
Smolen, J.S., Aletaha, D., Barton, A., Burmester, G.R., Emery, P., Firestein, G.S., Kavanaugh, A., McInnes, I.B., Solomon, D.H., Strand, V., et al. Rheumatoid arthritis. Nat. Rev. Dis. Prim., 4, 2018, 18001, 10.1038/nrdp.2018.1.
van Beers, J.J.B.C., Willemze, A., Jansen, J.J., Engbers, G.H.M., Salden, M., Raats, J., Drijfhout, J.W., van der Helm-van Mil, A.H.M., Toes, R.E.M., Pruijn, G.J.M., ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression. Arthritis Res. Ther., 15, 2013, R140, 10.1186/ar4322.
Rantapää-Dahlqvist, S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand. J. Rheumatol. 34, 83–96, doi:10.1080/03009740510017689.
Wysocki, T., Olesińska, M., Paradowska-Gorycka, A., Current understanding of an emerging role of HLA-DRB1 gene in rheumatoid arthritis-from research to clinical practice. Cells, 9, 2020, 10.3390/cells9051127.
Ridgley, L.A., Anderson, A.E., Pratt, A.G., What are the dominant cytokines in early rheumatoid arthritis?. Curr. Opin. Rheumatol. 30 (2018), 207–214, 10.1097/BOR.0000000000000470.
Findeisen, K.E., Sewell, J., Ostor, A.J.K., Biological therapies for rheumatoid arthritis: an overview for the clinician. Biologics 15 (2021), 343–352, 10.2147/BTT.S252575.
Friedman, B., Cronstein, B., Methotrexate mechanism in treatment of rheumatoid arthritis. Jt. bone spine 86 (2019), 301–307, 10.1016/j.jbspin.2018.07.004.
Behrens, E.M., Koretzky, G.A., Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol. 69 (2017), 1135–1143, 10.1002/art.40071.
McInnes, I.B., Liew, F.Y., Cytokine networks–towards new therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1 (2005), 31–39, 10.1038/ncprheum0020.
Alunno, A., Manetti, M., Caterbi, S., Ibba-Manneschi, L., Bistoni, O., Bartoloni, E., Valentini, V., Terenzi, R., Gerli, R., Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. Mediat. Inflamm., 2015, 751793, 10.1155/2015/751793 2015.
Tardito, S., Martinelli, G., Soldano, S., Paolino, S., Pacini, G., Patane, M., Alessandri, E., Smith, V., Cutolo, M., Macrophage M1/M2 polarization and rheumatoid arthritis: a systematic review. Autoimmun. Rev., 18, 2019, 102397, 10.1016/j.autrev.2019.102397.
Jang, S., Kwon, E.-J., Lee, J.J., Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int. J. Mol. Sci., 2022, 23, 10.3390/ijms23020905.
Perlman, H., Bradley, K., Liu, H., Cole, S., Shamiyeh, E., Smith, R.C., Walsh, K., Fiore, S., Koch, A.E., Firestein, G.S., et al. IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J. Immunol. 170 (2003), 838–845, 10.4049/jimmunol.170.2.838.
Migita, K., Iwanaga, N., Izumi, Y., Kawahara, C., Kumagai, K., Nakamura, T., Koga, T., Kawakami, A., TNF-α-induced miR-155 regulates IL-6 signaling in rheumatoid synovial fibroblasts. BMC Res. Notes, 10, 2017, 403, 10.1186/s13104-017-2715-5.
de Oliveira, P.G., Farinon, M., Sanchez-Lopez, E., Miyamoto, S., Guma, M., Fibroblast-like synoviocytes glucose metabolism as a therapeutic target in rheumatoid arthritis. Front. Immunol., 10, 2019, 1743, 10.3389/fimmu.2019.01743.
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M.J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M.G., Oliva, B., et al. Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach. Pharmacol. Rev. 70 (2018), 348–383, 10.1124/pr.117.014753.
Bjelakovic, G., Nikolova, D., Gluud, L.L., Simonetti, R.G., Gluud, C., Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297 (2007), 842–857, 10.1001/jama.297.8.842.
Bjelakovic, G., Nikolova, D., Gluud, L.L., Simonetti, R.G., Gluud, C., Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst. Rev., 2012, CD007176, 10.1002/14651858.CD007176.pub2.
Chadha, S., Behl, T., Kumar, A., Khullar, G., Arora, S., Role of Nrf2 in rheumatoid arthritis. Curr. Res. Transl. Med. 68 (2020), 171–181, 10.1016/j.retram.2020.05.002.
Kaur, G., Sharma, A., Bhatnagar, A., Role of oxidative stress in pathophysiology of rheumatoid arthritis: insights into NRF2-KEAP1 signalling. Autoimmunity 54 (2021), 385–397, 10.1080/08916934.2021.1963959.
da Fonseca, L.J.S., Nunes-Souza, V., Goulart, M.O.F., Rabelo, L.A., Oxidative stress in rheumatoid arthritis: what the future might hold regarding novel biomarkers and add-on therapies. Oxid. Med. Cell. Longev., 2019, 7536805, 10.1155/2019/7536805 2019.
Quiñonez-Flores, C.M., González-Chávez, S.A., Del Río Nájera, D., Pacheco-Tena, C., Oxidative stress relevance in the pathogenesis of the rheumatoid arthritis: a systematic review. BioMed Res. Int., 2016, 6097417, 10.1155/2016/6097417 2016.
Fearon, U., Canavan, M., Biniecka, M., Veale, D.J., Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. Nat. Rev. Rheumatol. 12 (2016), 385–397, 10.1038/nrrheum.2016.69.
Le Rossignol, S., Ketheesan, N., Haleagrahara, N., Redox-sensitive transcription factors play a significant role in the development of rheumatoid arthritis. Int. Rev. Immunol. 37 (2018), 129–143, 10.1080/08830185.2017.1363198.
Fukai, T., Ushio-Fukai, M., Cross-Talk between NADPH oxidase and mitochondria: role in ROS signaling and angiogenesis. Cells, 9, 2020, 10.3390/cells9081849.
Taylor, J.P., Tse, H.M., The role of NADPH oxidases in infectious and inflammatory diseases. Redox Biol., 48, 2021, 102159, 10.1016/j.redox.2021.102159.
Yazdanpanah, B., Wiegmann, K., Tchikov, V., Krut, O., Pongratz, C., Schramm, M., Kleinridders, A., Wunderlich, T., Kashkar, H., Utermöhlen, O., et al. Riboflavin kinase couples TNF receptor 1 to NADPH oxidase. Nature 460 (2009), 1159–1163, 10.1038/nature08206.
Blaser, H., Dostert, C., Mak, T.W., Brenner, D., TNF and ROS crosstalk in inflammation. Trends Cell Biol. 26 (2016), 249–261, 10.1016/j.tcb.2015.12.002.
Pelletier, M., Maggi, L., Micheletti, A., Lazzeri, E., Tamassia, N., Costantini, C., Cosmi, L., Lunardi, C., Annunziato, F., Romagnani, S., et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115 (2010), 335–343, 10.1182/blood-2009-04-216085.
Edwards, S.W., Hallett, M.B., Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol. Today 18 (1997), 320–324, 10.1016/s0167-5699(97)01087-6.
Colotta, F., Re, F., Polentarutti, N., Sozzani, S., Mantovani, A., Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80 (1992), 2012–2020.
Song, W., Ye, J., Pan, N., Tan, C., Herrmann, M., Neutrophil extracellular traps tied to rheumatoid arthritis: points to ponder. Front. Immunol., 11, 2020, 578129, 10.3389/fimmu.2020.578129.
Khandpur, R., Carmona-Rivera, C., Vivekanandan-Giri, A., Gizinski, A., Yalavarthi, S., Knight, J.S., Friday, S., Li, S., Patel, R.M., Subramanian, V., et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci. Transl. Med., 5, 2013, 178ra40, 10.1126/scitranslmed.3005580.
Fuchs, T.A., Abed, U., Goosmann, C., Hurwitz, R., Schulze, I., Wahn, V., Weinrauch, Y., Brinkmann, V., Zychlinsky, A., Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 176 (2007), 231–241, 10.1083/jcb.200606027.
Pérez-Sánchez, C., Ruiz-Limón, P., Aguirre, M.A., Jiménez-Gómez, Y., Arias-de la Rosa, I., Ábalos-Aguilera, M.C., Rodriguez-Ariza, A., Castro-Villegas, M.C., Ortega-Castro, R., Segui, P., et al. Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. J. Autoimmun. 82 (2017), 31–40, 10.1016/j.jaut.2017.04.007.
Carmona-Rivera, C., Carlucci, P.M., Moore, E., Lingampalli, N., Uchtenhagen, H., James, E., Liu, Y., Bicker, K.L., Wahamaa, H., Hoffmann, V., et al. Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis. Sci. Immunol., 2, 2017, 10.1126/sciimmunol.aag3358.
Wright, H.L., Cox, T., Moots, R.J., Edwards, S.W., Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis. J. Leukoc. Biol. 101 (2017), 785–795, 10.1189/jlb.5A0616-258R.
Capsoni, F., Sarzi-Puttini, P., Atzeni, F., Minonzio, F., Bonara, P., Doria, A., Carrabba, M., Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Arthritis Res. Ther. 7 (2005), R250–R255, 10.1186/ar1477.
Nzeusseu Toukap, A., Delporte, C., Noyon, C., Franck, T., Rousseau, A., Serteyn, D., Raes, M., Vanhaeverbeek, M., Moguilevsky, N., Nève, J., et al. Myeloperoxidase and its products in synovial fluid of patients with treated or untreated rheumatoid arthritis. Free Radic. Res. 48 (2014), 461–465, 10.3109/10715762.2014.886327.
Draibe, J., Salama, A.D., Association of ANCA associated vasculitis and rheumatoid arthritis: a lesser recognized overlap syndrome. SpringerPlus, 4, 2015, 50, 10.1186/s40064-015-0835-8.
Clayton, S.A., MacDonald, L., Kurowska-Stolarska, M., Clark, A.R., Mitochondria as key players in the pathogenesis and treatment of rheumatoid arthritis. Front. Immunol., 12, 2021, 673916, 10.3389/fimmu.2021.673916.
Hofmann, B., Didier, D., [Use of a tooth graft in mentoplasty. Apropos of a case]. Rev. Stomatol. Chir. Maxillofac. 89 (1988), 132–134.
Griffiths, H.R., Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease?. Autoimmun. Rev. 7 (2008), 544–549, 10.1016/j.autrev.2008.04.013.
Hoffmann, M.H., Griffiths, H.R., The dual role of Reactive Oxygen Species in autoimmune and inflammatory diseases: evidence from preclinical models. Free Radic. Biol. Med. 125 (2018), 62–71, 10.1016/j.freeradbiomed.2018.03.016.
Mousavi, M.J., Karami, J., Aslani, S., Tahmasebi, M.N., Vaziri, A.S., Jamshidi, A., Farhadi, E., Mahmoudi, M., Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe. Auto- Immun. highlights, 12, 2021, 3, 10.1186/s13317-020-00145-x.
Lee, S.-Y., Kwok, S.-K., Son, H.-J., Ryu, J.-G., Kim, E.-K., Oh, H.-J., Cho, M.-L., Ju, J.H., Park, S.-H., Kim, H.-Y., IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis Res. Ther., 15, 2013, R31, 10.1186/ar4179.
Phull, A.-R., Nasir, B., Haq, I.U., Kim, S.J., Oxidative stress, consequences and ROS mediated cellular signaling in rheumatoid arthritis. Chem. Biol. Interact. 281 (2018), 121–136, 10.1016/j.cbi.2017.12.024.
Nisimoto, Y., Diebold, B.A., Cosentino-Gomes, D., Constentino-Gomes, D., Lambeth, J.D., Nox4: a hydrogen peroxide-generating oxygen sensor. Biochemistry 53 (2014), 5111–5120, 10.1021/bi500331y.
Lee, H.-R., Yoo, S.-J., Kim, J., Yoo, I.S., Park, C.K., Kang, S.W., The effect of nicotinamide adenine dinucleotide phosphate oxidase 4 on migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res. Ther., 22, 2020, 116, 10.1186/s13075-020-02204-0.
Manning, J.E., Lewis, J.W., Marsh, L.-J., McGettrick, H.M., Insights into leukocyte trafficking in inflammatory arthritis - imaging the joint. Front. Cell Dev. Biol., 9, 2021, 635102, 10.3389/fcell.2021.635102.
Lee, H.-R., Yoo, S.-J., Kim, J., Park, C.K., Kang, S.W., Reduction of oxidative stress in peripheral blood mononuclear cells attenuates the inflammatory response of fibroblast-like synoviocytes in rheumatoid arthritis. Int. J. Mol. Sci., 22, 2021, 10.3390/ijms222212411.
Martinvalet, D., Walch, M., Editorial: the role of reactive oxygen species in protective immunity. Front. Immunol., 12, 2021, 832946, 10.3389/fimmu.2021.832946.
Cubillos-Ruiz, J.R., Silberman, P.C., Rutkowski, M.R., Chopra, S., Perales-Puchalt, A., Song, M., Zhang, S., Bettigole, S.E., Gupta, D., Holcomb, K., et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161 (2015), 1527–1538, 10.1016/j.cell.2015.05.025.
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat. Immunol. 18 (2017), 1332–1341, 10.1038/ni.3868.
Groen, A., Lemeer, S., van der Wijk, T., Overvoorde, J., Heck, A.J.R., Ostman, A., Barford, D., Slijper, M., den Hertog, J., Differential oxidation of protein-tyrosine phosphatases. J. Biol. Chem. 280 (2005), 10298–10304, 10.1074/jbc.M412424200.
Matsui, R., Ferran, B., Oh, A., Croteau, D., Shao, D., Han, J., Pimentel, D.R., Bachschmid, M.M., Redox regulation via glutaredoxin-1 and protein S-glutathionylation. Antioxidants Redox Signal. 32 (2020), 677–700, 10.1089/ars.2019.7963.
Stanoev, A., Mhamane, A., Schuermann, K.C., Grecco, H.E., Stallaert, W., Baumdick, M., Brüggemann, Y., Joshi, M.S., Roda-Navarro, P., Fengler, S., et al. Interdependence between EGFR and phosphatases spatially established by vesicular dynamics generates a growth factor sensing and responding network. Cell Syst 7 (2018), 295–309, 10.1016/j.cels.2018.06.006 e11.
Piva, R.; Belardo, G.; Santoro, M.G. NF-kappaB: a stress-regulated switch for cell survival. Antioxidants Redox Signal. 8, 478–486, doi:10.1089/ars.2006.8.478.
Makarov, S.S., NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res. 3 (2001), 200–206, 10.1186/ar300.
Torices, S., Julia, A., Muñoz, P., Varela, I., Balsa, A., Marsal, S., Fernández-Nebro, A., Blanco, F., López-Hoyos, M., Martinez-Taboada, V., et al. A functional variant of TLR10 modifies the activity of NFkB and may help predict a worse prognosis in patients with rheumatoid arthritis. Arthritis Res. Ther., 18, 2016, 221, 10.1186/s13075-016-1113-z.
Firestein, G.S., Yeo, M., Zvaifler, N.J., Apoptosis in rheumatoid arthritis synovium. J. Clin. Invest. 96 (1995), 1631–1638, 10.1172/JCI118202.
Jeong, S.-J., Pise-Masison, C.A., Radonovich, M.F., Park, H.U., Brady, J.N., A novel NF-kappaB pathway involving IKKbeta and p65/RelA Ser-536 phosphorylation results in p53 Inhibition in the absence of NF-kappaB transcriptional activity. J. Biol. Chem. 280 (2005), 10326–10332, 10.1074/jbc.M412643200.
Kaur, I., Behl, T., Bungau, S., Kumar, A., Mehta, V., Setia, D., Uddin, M.S., Zengin, G., Aleya, L., Arora, S., Exploring the therapeutic promise of targeting HMGB1 in rheumatoid arthritis. Life Sci., 258, 2020, 118164, 10.1016/j.lfs.2020.118164.
Wu, Y.-Y., Li, X.-F., Wu, S., Niu, X.-N., Yin, S.-Q., Huang, C., Li, J., Role of the S100 protein family in rheumatoid arthritis. Arthritis Res. Ther., 24, 2022, 35, 10.1186/s13075-022-02727-8.
Tanaka, S., Tanaka, Y., Ishiguro, N., Yamanaka, H., Takeuchi, T., RANKL: a therapeutic target for bone destruction in rheumatoid arthritis. Mod. Rheumatol. 28 (2018), 9–16, 10.1080/14397595.2017.1369491.
Yang, J., Wang, J., Liang, X., Zhao, H., Lu, J., Ma, Q., Jing, B., Tian, F., IL-1β increases the expression of inflammatory factors in synovial fluid-derived fibroblast-like synoviocytes via activation of the NF-κB-mediated ERK-STAT1 signaling pathway. Mol. Med. Rep. 20 (2019), 4993–5001, 10.3892/mmr.2019.10759.
Abdel Meguid, M.H., Hamad, Y.H., Swilam, R.S., Barakat, M.S., Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol. Int. 33 (2013), 697–703, 10.1007/s00296-012-2375-7.
Sutterwala, F.S., Haasken, S., Cassel, S.L., Mechanism of NLRP3 inflammasome activation. Ann. N. Y. Acad. Sci. 1319 (2014), 82–95, 10.1111/nyas.12458.
Verma, S., De Jesus, P., Chanda, S.K., Verma, I.M., SNW1, a novel transcriptional regulator of the NF-κB pathway. Mol. Cell Biol., 39, 2019, 10.1128/MCB.00415-18.
Gardam, S., Sierro, F., Basten, A., Mackay, F., Brink, R., TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 28 (2008), 391–401, 10.1016/j.immuni.2008.01.009.
Lee, H.-Y., Jeon, H.-S., Song, E.-K., Han, M.-K., Park, S.-I., Lee, S.-I., Yun, H.-J., Kim, J.-R., Kim, J.-S., Lee, Y.-C., et al. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-kappaB-dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum. 54 (2006), 1747–1758, 10.1002/art.21873.
Herb, M., Gluschko, A., Wiegmann, K., Farid, A., Wolf, A., Utermöhlen, O., Krut, O., Krönke, M., Schramm, M., Mitochondrial reactive oxygen species enable proinflammatory signaling through disulfide linkage of NEMO. Sci. Signal., 12, 2019, 10.1126/scisignal.aar5926.
Reynaert, N.L., van der Vliet, A., Guala, A.S., McGovern, T., Hristova, M., Pantano, C., Heintz, N.H., Heim, J., Ho, Y.-S., Matthews, D.E., et al. Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. Proc. Natl. Acad. Sci. U. S. A 103 (2006), 13086–13091, 10.1073/pnas.0603290103.
Schoonbroodt, S., Ferreira, V., Best-Belpomme, M., Boelaert, J.R., Legrand-Poels, S., Korner, M., Piette, J., Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I kappa B alpha in NF-kappa B activation by an oxidative stress. J. Immunol. 164 (2000), 4292–4300, 10.4049/jimmunol.164.8.4292.
Imbert, V., Rupec, R.A., Livolsi, A., Pahl, H.L., Traenckner, E.B., Mueller-Dieckmann, C., Farahifar, D., Rossi, B., Auberger, P., Baeuerle, P.A., et al. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 86 (1996), 787–798, 10.1016/s0092-8674(00)80153-1.
Malemud, C.J., The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?. Future Med. Chem. 7 (2015), 1137–1147, 10.4155/fmc.15.55.
Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11 (2011), 85–95, 10.1038/nrc2981.
Chatterjee, S., Browning, E.A., Hong, N., DeBolt, K., Sorokina, E.M., Liu, W., Birnbaum, M.J., Fisher, A.B., Membrane depolarization is the trigger for PI3K/Akt activation and leads to the generation of ROS. Am. J. Physiol. Heart Circ. Physiol. 302 (2012), H105–H114, 10.1152/ajpheart.00298.2011.
Hirota, K., Matsui, M., Iwata, S., Nishiyama, A., Mori, K., Yodoi, J., AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. U. S. A 94 (1997), 3633–3638, 10.1073/pnas.94.8.3633.
Hirota, K., Murata, M., Sachi, Y., Nakamura, H., Takeuchi, J., Mori, K., Yodoi, J., Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J. Biol. Chem. 274 (1999), 27891–27897, 10.1074/jbc.274.39.27891.
Singh, A.K., Awasthi, D., Dubey, M., Nagarkoti, S., Kumar, A., Chandra, T., Barthwal, M.K., Tripathi, A.K., Dikshit, M., High oxidative stress adversely affects NFκB mediated induction of inducible nitric oxide synthase in human neutrophils: implications in chronic myeloid leukemia. Nitric oxide Biol. Chem. 58 (2016), 28–41, 10.1016/j.niox.2016.06.002.
Ando, K., Hirao, S., Kabe, Y., Ogura, Y., Sato, I., Yamaguchi, Y., Wada, T., Handa, H., A new APE1/Ref-1-dependent pathway leading to reduction of NF-kappaB and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res. 36 (2008), 4327–4336, 10.1093/nar/gkn416.
Mangiapane, G.; Parolini, I.; Conte, K.; Malfatti, M.C.; Corsi, J.; Sanchez, M.; Pietrantoni, A.; D'Agostino, V.G.; Tell, G. Enzymatically active apurinic/apyrimidinic endodeoxyribonuclease 1 is released by mammalian cells through exosomes. J. Biol. Chem. 296, 100569, doi:10.1016/j.jbc.2021.100569.
Yoo, I.S., Lee, Y.-R., Kang, S.W., Kim, J., Joo, H.-K., Yoo, S.-J., Park, C.K., Lee, H.-R., Park, J.A., Jeon, B.-H., Elevated APE1/ref-1 levels of synovial fluids in patients with rheumatoid arthritis: reflection of disease activity. J. Clin. Med., 2021, 10, 10.3390/jcm10225324.
Joo, H.K., Lee, Y.R., Lee, E.-O., Park, M.S., Choi, S., Kim, C.-S., Park, J.-B., Jeon, B.H., The extracellular role of Ref-1 as anti-inflammatory function in lipopolysaccharide-induced septic mice. Free Radic. Biol. Med. 139 (2019), 16–23, 10.1016/j.freeradbiomed.2019.05.013.
Hayes, J.D., Dinkova-Kostova, A.T., The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 39 (2014), 199–218, 10.1016/j.tibs.2014.02.002.
Cuadrado, A., Rojo, A.I., Wells, G., Hayes, J.D., Cousin, S.P., Rumsey, W.L., Attucks, O.C., Franklin, S., Levonen, A.-L., Kensler, T.W., et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat. Rev. Drug Discov. 18 (2019), 295–317, 10.1038/s41573-018-0008-x.
Itoh, K., Igarashi, K., Hayashi, N., Nishizawa, M., Yamamoto, M., Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol. Cell Biol. 15 (1995), 4184–4193, 10.1128/MCB.15.8.4184.
Wang, P., Song, J., Ye, D. CRL3s, The BTB-CUL3-RING E3 ubiquitin ligases. Adv. Exp. Med. Biol. 1217 (2020), 211–223, 10.1007/978-981-15-1025-0_13.
Tong, K.I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., Yamamoto, M., Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol. Cell Biol. 26 (2006), 2887–2900, 10.1128/MCB.26.8.2887-2900.2006.
Dinkova-Kostova, A.T., Holtzclaw, W.D., Cole, R.N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., Talalay, P., Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. U. S. A, 99, 2002, 11908, 10.1073/pnas.172398899 –13.
Zhang, D.D., Hannink, M., Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell Biol. 23 (2003), 8137–8151, 10.1128/MCB.23.22.8137-8151.2003.
Raghunath, A., Sundarraj, K., Nagarajan, R., Arfuso, F., Bian, J., Kumar, A.P., Sethi, G., Perumal, E., Antioxidant response elements: discovery, classes, regulation and potential applications. Redox Biol. 17 (2018), 297–314, 10.1016/j.redox.2018.05.002.
Kuosmanen, S.M., Viitala, S., Laitinen, T., Peräkylä, M., Pölönen, P., Kansanen, E., Leinonen, H., Raju, S., Wienecke-Baldacchino, A., Närvänen, A., et al. The effects of sequence variation on genome-wide NRF2 binding–new target genes and regulatory SNPs. Nucleic Acids Res. 44 (2016), 1760–1775, 10.1093/nar/gkw052.
Jyrkkänen, H.-K., Kansanen, E., Inkala, M., Kivelä, A.M., Hurttila, H., Heinonen, S.E., Goldsteins, G., Jauhiainen, S., Tiainen, S., Makkonen, H., et al. Nrf2 regulates antioxidant gene expression evoked by oxidized phospholipids in endothelial cells and murine arteries in vivo. Circ. Res. 103 (2008), e1–9, 10.1161/CIRCRESAHA.108.176883.
Harris, I.S., Treloar, A.E., Inoue, S., Sasaki, M., Gorrini, C., Lee, K.C., Yung, K.Y., Brenner, D., Knobbe-Thomsen, C.B., Cox, M.A., et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27 (2015), 211–222, 10.1016/j.ccell.2014.11.019.
Ghezzi, P.; Di Simplicio, P. Regulation of protein function by glutathionylation. In Glutathione and Sulfur Amino Acids in Human Health and Disease; John Wiley & Sons, Inc.: Hoboken, NJ, USA; pp. 189–209.
Dagnell, M., Pace, P.E., Cheng, Q., Frijhoff, J., Östman, A., Arnér, E.S.J., Hampton, M.B., Winterbourn, C.C., Thioredoxin reductase 1 and NADPH directly protect protein tyrosine phosphatase 1B from inactivation during H2O2 exposure. J. Biol. Chem. 292 (2017), 14371–14380, 10.1074/jbc.M117.793745.
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., Motohashi, H., Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22 (2012), 66–79, 10.1016/j.ccr.2012.05.016.
He, F., Antonucci, L., Karin, M., NRF2 as a regulator of cell metabolism and inflammation in cancer. Carcinogenesis 41 (2020), 405–416, 10.1093/carcin/bgaa039.
van der Reest, J., Lilla, S., Zheng, L., Zanivan, S., Gottlieb, E., Proteome-wide analysis of cysteine oxidation reveals metabolic sensitivity to redox stress. Nat. Commun., 9, 2018, 1581, 10.1038/s41467-018-04003-3.
Lampropoulou, V., Sergushichev, A., Bambouskova, M., Nair, S., Vincent, E.E., Loginicheva, E., Cervantes-Barragan, L., Ma, X., Huang, S.C.-C., Griss, T., et al. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metabol. 24 (2016), 158–166, 10.1016/j.cmet.2016.06.004.
Mills, E.L., Ryan, D.G., Prag, H.A., Dikovskaya, D., Menon, D., Zaslona, Z., Jedrychowski, M.P., Costa, A.S.H., Higgins, M., Hams, E., et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature 556 (2018), 113–117, 10.1038/nature25986.
Ryan, D.G., Knatko, E.V., Casey, A.M., Hukelmann, J.L., Dayalan Naidu, S., Brenes, A.J., Ekkunagul, T., Baker, C., Higgins, M., Tronci, L., et al. Nrf2 activation reprograms macrophage intermediary metabolism and suppresses the type I interferon response. iScience, 25, 2022, 103827, 10.1016/j.isci.2022.103827.
Castañeda-Delgado, J.E., Bastián-Hernandez, Y., Macias-Segura, N., Santiago-Algarra, D., Castillo-Ortiz, J.D., Alemán-Navarro, A.L., Martínez-Tejada, P., Enciso-Moreno, L., Garcia-De Lira, Y., Olguín-Calderón, D., et al. Type I interferon gene response is increased in early and established rheumatoid arthritis and correlates with autoantibody production. Front. Immunol., 8, 2017, 285, 10.3389/fimmu.2017.00285.
Holmström, K.M., Baird, L., Zhang, Y., Hargreaves, I., Chalasani, A., Land, J.M., Stanyer, L., Yamamoto, M., Dinkova-Kostova, A.T., Abramov, A.Y., Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. Biol. Open 2 (2013), 761–770, 10.1242/bio.20134853.
Dinkova-Kostova, A.T., Abramov, A.Y., The emerging role of Nrf2 in mitochondrial function. Free Radic. Biol. Med. 88 (2015), 179–188, 10.1016/j.freeradbiomed.2015.04.036.
Garcia-Carbonell, R., Divakaruni, A.S., Lodi, A., Vicente-Suarez, I., Saha, A., Cheroutre, H., Boss, G.R., Tiziani, S., Murphy, A.N., Guma, M., Critical role of glucose metabolism in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheumatol. 68 (2016), 1614–1626, 10.1002/art.39608.
Du, Y., Wang, Q., Tian, N., Lu, M., Zhang, X.-L., Dai, S.-M., Knockdown of nrf2 exacerbates TNF-α-induced proliferation and invasion of rheumatoid arthritis fibroblast-like synoviocytes through activating JNK pathway. J. Immunol. Res., 2020, 6670464, 10.1155/2020/6670464 2020.
Fu, J., Xiong, Z., Huang, C., Li, J., Yang, W., Han, Y., Paiboonrungruan, C., Major, M.B., Chen, K.-N., Kang, X., et al. Hyperactivity of the transcription factor Nrf2 causes metabolic reprogramming in mouse esophagus. J. Biol. Chem. 294 (2019), 327–340, 10.1074/jbc.RA118.005963.
Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D.R., et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 35 (2003), 238–245, 10.1038/ng1248.
Taguchi, K., Maher, J.M., Suzuki, T., Kawatani, Y., Motohashi, H., Yamamoto, M., Genetic analysis of cytoprotective functions supported by graded expression of Keap1. Mol. Cell Biol. 30 (2010), 3016–3026, 10.1128/MCB.01591-09.
Jikimoto, T., Nishikubo, Y., Koshiba, M., Kanagawa, S., Morinobu, S., Morinobu, A., Saura, R., Mizuno, K., Kondo, S., Toyokuni, S., et al. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol. Immunol. 38 (2002), 765–772, 10.1016/s0161-5890(01)00113-4.
Hawkes, H.-J.K., Karlenius, T.C., Tonissen, K.F., Regulation of the human thioredoxin gene promoter and its key substrates: a study of functional and putative regulatory elements. Biochim. Biophys. Acta 1840 (2014), 303–314, 10.1016/j.bbagen.2013.09.013.
Su, X., Huang, Q., Chen, J., Wang, M., Pan, H., Wang, R., Zhou, H., Zhou, Z., Liu, J., Yang, F., et al. Calycosin suppresses expression of pro-inflammatory cytokines via the activation of p62/Nrf2-linked heme oxygenase 1 in rheumatoid arthritis synovial fibroblasts. Pharmacol. Res. 113 (2016), 695–704, 10.1016/j.phrs.2016.09.031.
Chu, J., Wang, X., Bi, H., Li, L., Ren, M., Wang, J., Dihydromyricetin relieves rheumatoid arthritis symptoms and suppresses expression of pro-inflammatory cytokines via the activation of Nrf2 pathway in rheumatoid arthritis model. Int. Immunopharm. 59 (2018), 174–180, 10.1016/j.intimp.2018.04.001.
Habib, E., Linher-Melville, K., Lin, H.-X., Singh, G., Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress. Redox Biol. 5 (2015), 33–42, 10.1016/j.redox.2015.03.003.
Lewerenz, J., Hewett, S.J., Huang, Y., Lambros, M., Gout, P.W., Kalivas, P.W., Massie, A., Smolders, I., Methner, A., Pergande, M., et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxidants Redox Signal. 18 (2013), 522–555, 10.1089/ars.2011.4391.
Shin, C.-S., Mishra, P., Watrous, J.D., Carelli, V., D'Aurelio, M., Jain, M., Chan, D.C., The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat. Commun., 8, 2017, 15074, 10.1038/ncomms15074.
Gout, P.W., Buckley, A.R., Simms, C.R., Bruchovsky, N., Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 15 (2001), 1633–1640, 10.1038/sj.leu.2402238.
Wruck, C.J., Fragoulis, A., Gurzynski, A., Brandenburg, L.-O., Kan, Y.W., Chan, K., Hassenpflug, J., Freitag-Wolf, S., Varoga, D., Lippross, S., et al. Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice. Ann. Rheum. Dis. 70 (2011), 844–850, 10.1136/ard.2010.132720.
Maicas, N., Ferrándiz, M.L., Brines, R., Ibáñez, L., Cuadrado, A., Koenders, M.I., van den Berg, W.B., Alcaraz, M.J., Deficiency of Nrf2 accelerates the effector phase of arthritis and aggravates joint disease. Antioxidants Redox Signal. 15 (2011), 889–901, 10.1089/ars.2010.3835.
Tavasolian, F., Hosseini, A.Z., Soudi, S., Naderi, M., Sahebkar, A., A systems biology approach for miRNA-mRNA expression patterns analysis in rheumatoid arthritis. Comb. Chem. High Throughput Screen. 24 (2021), 195–212, 10.2174/1386207323666200605150024.
Cuadrado, A., Martín-Moldes, Z., Ye, J., Lastres-Becker, I., Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation. J. Biol. Chem. 289 (2014), 15244–15258, 10.1074/jbc.M113.540633.
Rushworth, S.A., Zaitseva, L., Murray, M.Y., Shah, N.M., Bowles, K.M., MacEwan, D.J., The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance. Blood 120 (2012), 5188–5198, 10.1182/blood-2012-04-422121.
Joshi, N., Werner, S., Nrf2 is highly expressed in neutrophils, but myeloid cell-derived Nrf2 is dispensable for wound healing in mice. PLoS One, 12, 2017, e0187162, 10.1371/journal.pone.0187162.
Kim, Y.R., Oh, J.E., Kim, M.S., Kang, M.R., Park, S.W., Han, J.Y., Eom, H.S., Yoo, N.J., Lee, S.H., Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J. Pathol. 220 (2010), 446–451, 10.1002/path.2653.
Trocoli, A., Djavaheri-Mergny, M., The complex interplay between autophagy and NF-κB signaling pathways in cancer cells. Am. J. Cancer Res. 1 (2011), 629–649.
Kim, J.-E., You, D.-J., Lee, C., Ahn, C., Seong, J.Y., Hwang, J.-I., Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation. Cell. Signal. 22 (2010), 1645–1654, 10.1016/j.cellsig.2010.06.004.
Bloom, M.J., Saksena, S.D., Swain, G.P., Behar, M.S., Yankeelov, T.E., Sorace, A.G., The effects of IKK-beta inhibition on early NF-kappa-B activation and transcription of downstream genes. Cell. Signal. 55 (2019), 17–25, 10.1016/j.cellsig.2018.12.004.
Kostyuk, S.V., Porokhovnik, L.N., Ershova, E.S., Malinovskaya, E.M., Konkova, M.S., Kameneva, L.V., Dolgikh, O.A., Veiko, V.P., Pisarev, V.M., Martynov, A.V., et al. Changes of KEAP1/NRF2 and IKB/NF-κB expression levels induced by cell-free DNA in different cell types. Oxid. Med. Cell. Longev., 2018, 1052413, 10.1155/2018/1052413 2018.
Rada, P., Rojo, A.I., Chowdhry, S., McMahon, M., Hayes, J.D., Cuadrado, A., SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell Biol. 31 (2011), 1121–1133, 10.1128/MCB.01204-10.
Kanarek, N., Ben-Neriah, Y., Regulation of NF-κB by ubiquitination and degradation of the IκBs. Immunol. Rev. 246 (2012), 77–94, 10.1111/j.1600-065X.2012.01098.x.
Zeisbrich, M., Yanes, R.E., Zhang, H., Watanabe, R., Li, Y., Brosig, L., Hong, J., Wallis, B.B., Giacomini, J.C., Assimes, T.L., et al. Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation. Ann. Rheum. Dis. 77 (2018), 1053–1062, 10.1136/annrheumdis-2017-212647.
Alcaraz, M.J., Ferrándiz, M.L., Relevance of Nrf2 and heme oxygenase-1 in articular diseases. Free Radic. Biol. Med. 157 (2020), 83–93, 10.1016/j.freeradbiomed.2019.12.007.
Kobayashi, H., Takeno, M., Saito, T., Takeda, Y., Kirino, Y., Noyori, K., Hayashi, T., Ueda, A., Ishigatsubo, Y., Regulatory role of heme oxygenase 1 in inflammation of rheumatoid arthritis. Arthritis Rheum. 54 (2006), 1132–1142, 10.1002/art.21754.
Kitamura, A., Nishida, K., Komiyama, T., Doi, H., Kadota, Y., Yoshida, A., Ozaki, T., Increased level of heme oxygenase-1 in rheumatoid arthritis synovial fluid. Mod. Rheumatol. 21 (2011), 150–157, 10.1007/s10165-010-0372-9.
Li, Y., Huang, B., Ye, T., Wang, Y., Xia, D., Qian, J., Physiological concentrations of bilirubin control inflammatory response by inhibiting NF-κB and inflammasome activation. Int. Immunopharm., 84, 2020, 106520, 10.1016/j.intimp.2020.106520.
Alam, J., Cook, J.L., How many transcription factors does it take to turn on the heme oxygenase-1 gene?. Am. J. Respir. Cell Mol. Biol. 36 (2007), 166–174, 10.1165/rcmb.2006-0340TR.
Xiao, W., Advances in NF-kappaB signaling transduction and transcription. Cell. Mol. Immunol. 1 (2004), 425–435.
Reichard, J.F., Motz, G.T., Puga, A., Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res. 35 (2007), 7074–7086, 10.1093/nar/gkm638.
Casares, L., García, V., Garrido-Rodríguez, M., Millán, E., Collado, J.A., García-Martín, A., Peñarando, J., Calzado, M.A., de la Vega, L., Muñoz, E., Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol., 28, 2020, 101321, 10.1016/j.redox.2019.101321.
Katoh, Y., Itoh, K., Yoshida, E., Miyagishi, M., Fukamizu, A., Yamamoto, M., Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Gene Cell. 6 (2001), 857–868, 10.1046/j.1365-2443.2001.00469.x.
Zhong, H., Voll, R.E., Ghosh, S., Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell. 1 (1998), 661–671, 10.1016/s1097-2765(00)80066-0.
De Guzman, R.N., Wojciak, J.M., Martinez-Yamout, M.A., Dyson, H.J., Wright, P.E., CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding. Biochemistry 44 (2005), 490–497, 10.1021/bi048161t.
Sterner, D.E., Berger, S.L., Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64 (2000), 435–459, 10.1128/MMBR.64.2.435-459.2000.
Glennon, V., Whittle, S.L., Hill, C.L., Johnston, R.V., Avery, J.C., Grobler, L., McKenzie, B.J., Cyril, S., Pardo Pardo, J., Buchbinder, R., Short-term glucocorticoids for flares in people with rheumatoid arthritis receiving disease-modifying anti-rheumatic drugs (DMARDs). Cochrane Database Syst. Rev., 2021, 2021, 10.1002/14651858.CD014898.
Koh, M.Y., Lemos, R., Liu, X., Powis, G., The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res. 71 (2011), 4015–4027, 10.1158/0008-5472.CAN-10-4142.
Yoo, S.-J., Lee, H.-R., Kim, J., Yoo, I.S., Park, C.K., Kang, S.W., Hypoxia-inducible factor-2 alpha regulates the migration of fibroblast-like synoviocytes via oxidative stress-induced CD70 expression in patients with rheumatoid arthritis. Int. J. Mol. Sci., 2022, 23, 10.3390/ijms23042342.
Liu, G.-H., Qu, J., Shen, X., NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim. Biophys. Acta 1783 (2008), 713–727, 10.1016/j.bbamcr.2008.01.002.
Ning, L., Rui, X., Bo, W., Qing, G., The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury. Cell Death Dis., 12, 2021, 734, 10.1038/s41419-021-04019-6.
Angiolilli, C., Kabala, P.A., Grabiec, A.M., Van Baarsen, I.M., Ferguson, B.S., García, S., Malvar Fernandez, B., McKinsey, T.A., Tak, P.P., Fossati, G., et al. Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. Ann. Rheum. Dis. 76 (2017), 277–285, 10.1136/annrheumdis-2015-209064.
Stein, B., Baldwin, A.S., Ballard, D.W., Greene, W.C., Angel, P., Herrlich, P., Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J. 12 (1993), 3879–3891, 10.1002/j.1460-2075.1993.tb06066.x.
Zolotukhin, P.V., Belanova, A.A., Feed-forward and feed-back circuits of the NRF2/AP-1 composite pathway. A Master Regulator of Oxidative Stress - the Transcription Factor Nrf2, 2016, InTech.
Venugopal, R., Jaiswal, A.K., Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. U. S. A, 93, 1996, 10.1073/pnas.93.25.14960 14960–5.
Müller-Ladner, U., Ospelt, C., Gay, S., Distler, O., Pap, T., Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Res. Ther., 9, 2007, 223, 10.1186/ar2337.
Korbecki, J., Simińska, D., Gąssowska-Dobrowolska, M., Listos, J., Gutowska, I., Chlubek, D., Baranowska-Bosiacka, I., Chronic and cycling hypoxia: drivers of cancer chronic inflammation through HIF-1 and NF-κB activation: a review of the molecular mechanisms. Int. J. Mol. Sci., 22, 2021, 10701, 10.3390/ijms221910701.
Lando, D., Peet, D.J., Whelan, D.A., Gorman, J.J., Whitelaw, M.L., Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 295 (2002), 858–861, 10.1126/science.1068592.
Thomas, L.W., Ashcroft, M., Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria. Cell. Mol. Life Sci. 76 (2019), 1759–1777, 10.1007/s00018-019-03039-y.
Westra, J., Brouwer, E., Bos, R., Posthumus, M.D., Doornbos-van der Meer, B., Kallenberg, C.G.M., Limburg, P.C., Regulation of cytokine-induced HIF-1alpha expression in rheumatoid synovial fibroblasts. Ann. N. Y. Acad. Sci. 1108 (2007), 340–348, 10.1196/annals.1422.035.
Guo, X., Chen, G., Hypoxia-inducible factor is critical for pathogenesis and regulation of immune cell functions in rheumatoid arthritis. Front. Immunol., 11, 2020, 10.3389/fimmu.2020.01668.
Hu, F., Mu, R., Zhu, J., Shi, L., Li, Y., Liu, X., Shao, W., Li, G., Li, M., Su, Y., et al. Hypoxia and hypoxia-inducible factor-1α provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis. Ann. Rheum. Dis. 73 (2014), 928–936, 10.1136/annrheumdis-2012-202444.
Hua, S., Dias, T.H., Hypoxia-inducible factor (HIF) as a target for novel therapies in rheumatoid arthritis. Front. Pharmacol., 7, 2016, 184, 10.3389/fphar.2016.00184.
Li, G.-Q., Zhang, Y., Liu, D., Qian, Y.-Y., Zhang, H., Guo, S.-Y., Sunagawa, M., Hisamitsu, T., Liu, Y.-Q., PI3 kinase/Akt/HIF-1α pathway is associated with hypoxia-induced epithelial–mesenchymal transition in fibroblast-like synoviocytes of rheumatoid arthritis. Mol. Cell. Biochem. 372 (2013), 221–231, 10.1007/s11010-012-1463-z.
Manuelli, V., Pecorari, C., Filomeni, G., Zito, E., Regulation of redox signaling in HIF-1-dependent tumor angiogenesis. FEBS J., 2021, 16110, 10.1111/febs.16110 febs.
Loboda, A., Stachurska, A., Florczyk, U., Rudnicka, D., Jazwa, A., Wegrzyn, J., Kozakowska, M., Stalinska, K., Poellinger, L., Levonen, A.-L., et al. HIF-1 induction attenuates Nrf2-dependent IL-8 expression in human endothelial cells. Antioxidants Redox Signal. 11 (2009), 1501–1517, 10.1089/ars.2008.2211.
Lin, H.-C., Su, S.-L., Lu, C.-Y., Lin, A.-H., Lin, W.-C., Liu, C.-S., Yang, Y.-C., Wang, H.-M., Lii, C.-K., Chen, H.-W., Andrographolide inhibits hypoxia-induced HIF-1α-driven endothelin 1 secretion by activating Nrf2/HO-1 and promoting the expression of prolyl hydroxylases 2/3 in human endothelial cells. Environ. Toxicol. 32 (2017), 918–930, 10.1002/tox.22293.
Carreau, A., El Hafny-Rahbi, B., Matejuk, A., Grillon, C., Kieda, C., Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J. Cell Mol. Med. 15 (2011), 1239–1253, 10.1111/j.1582-4934.2011.01258.x.
Keeley, T.P., Mann, G.E., Defining physiological normoxia for improved translation of cell physiology to animal models and humans. Physiol. Rev. 99 (2019), 161–234, 10.1152/physrev.00041.2017.
Altindag, O., Karakoc, M., Kocyigit, A., Celik, H., Soran, N., Increased DNA damage and oxidative stress in patients with rheumatoid arthritis. Clin. Biochem. 40 (2007), 167–171, 10.1016/j.clinbiochem.2006.10.006.
Lee, J.-W., Lee, J., Um, S.H., Moon, E.-Y., Synovial cell death is regulated by TNF-α-induced expression of B-cell activating factor through an ERK-dependent increase in hypoxia-inducible factor-1α. Cell Death Dis., 8, 2017, e2727, 10.1038/cddis.2017.26.
Yamanishi, Y., Boyle, D.L., Rosengren, S., Green, D.R., Zvaifler, N.J., Firestein, G.S., Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc. Natl. Acad. Sci. U. S. A 99 (2002), 10025–10030, 10.1073/pnas.152333199.
Engeland, K., Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 29 (2022), 946–960, 10.1038/s41418-022-00988-z.
Trakala, M., Arias, C.F., García, M.I., Moreno-Ortiz, M.C., Tsilingiri, K., Fernández, P.J., Mellado, M., Díaz-Meco, M.T., Moscat, J., Serrano, M., et al. Regulation of macrophage activation and septic shock susceptibility via p21(WAF1/CIP1). Eur. J. Immunol. 39 (2009), 810–819, 10.1002/eji.200838676.
Rackov, G., Hernández-Jiménez, E., Shokri, R., Carmona-Rodríguez, L., Mañes, S., Álvarez-Mon, M., López-Collazo, E., Martínez-A, C., Balomenos, D., p21 mediates macrophage reprogramming through regulation of p50-p50 NF-κB and IFN-β. J. Clin. Invest. 126 (2016), 3089–3103, 10.1172/JCI83404.
Woods, J.M., Klosowska, K., Spoden, D.J., Stumbo, N.G., Paige, D.J., Scatizzi, J.C., Volin, M.V., Rao, M.S., Perlman, H., A cell-cycle independent role for p21 in regulating synovial fibroblast migration in rheumatoid arthritis. Arthritis Res. Ther., 8, 2006, R113, 10.1186/ar1999.
Malhotra, D., Portales-Casamar, E., Singh, A., Srivastava, S., Arenillas, D., Happel, C., Shyr, C., Wakabayashi, N., Kensler, T.W., Wasserman, W.W., et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38 (2010), 5718–5734, 10.1093/nar/gkq212.
Kobayashi, E.H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat. Commun., 7, 2016, 11624, 10.1038/ncomms11624.
Jiang, Q., Wang, X., Huang, E., Wang, Q., Wen, C., Yang, G., Lu, L., Cui, D., Inflammasome and its therapeutic targeting in rheumatoid arthritis. Front. Immunol., 12, 2021, 816839, 10.3389/fimmu.2021.816839.
Martinon, F., Burns, K., Tschopp, J., The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell. 10 (2002), 417–426, 10.1016/s1097-2765(02)00599-3.
Christgen, S., Place, D.E., Kanneganti, T.-D., Toward targeting inflammasomes: insights into their regulation and activation. Cell Res. 30 (2020), 315–327, 10.1038/s41422-020-0295-8.
Zheng, D., Liwinski, T., Elinav, E., Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov, 6, 2020, 36, 10.1038/s41421-020-0167-x.
Tastan, B., Arioz, B.I., Genc, S., Targeting NLRP3 inflammasome with Nrf2 inducers in central nervous system disorders. Front. Immunol., 13, 2022, 865772, 10.3389/fimmu.2022.865772.
Matikainen, S., Nyman, T.A., Cypryk, W., Function and regulation of noncanonical caspase-4/5/11 inflammasome. J. Immunol. 204 (2020), 3063–3069, 10.4049/jimmunol.2000373.
Olcum, M., Tastan, B., Kiser, C., Genc, S., Genc, K., Microglial NLRP3 inflammasome activation in multiple sclerosis. Adv. Protein Chem. Struct. Biol. 119 (2020), 247–308, 10.1016/bs.apcsb.2019.08.007.
Jing, M., Yang, J., Zhang, L., Liu, J., Xu, S., Wang, M., Zhang, L., Sun, Y., Yan, W., Hou, G., et al. Celastrol inhibits rheumatoid arthritis through the ROS-NF-κB-NLRP3 inflammasome axis. Int. Immunopharm., 98, 2021, 107879, 10.1016/j.intimp.2021.107879.
Simard, J.-C., Cesaro, A., Chapeton-Montes, J., Tardif, M., Antoine, F., Girard, D., Tessier, P.A., S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-κB(1.). PLoS One, 8, 2013, e72138, 10.1371/journal.pone.0072138.
Zhou, R., Yazdi, A.S., Menu, P., Tschopp, J., A role for mitochondria in NLRP3 inflammasome activation. Nature 469 (2011), 221–225, 10.1038/nature09663.
Qiu, Y., Huang, Y., Chen, M., Yang, Y., Li, X., Zhang, W., Mitochondrial DNA in NLRP3 inflammasome activation. Int. Immunopharm., 108, 2022, 108719, 10.1016/j.intimp.2022.108719.
Weyand, C.M., Wu, B., Goronzy, J.J., The metabolic signature of T cells in rheumatoid arthritis. Curr. Opin. Rheumatol. 32 (2020), 159–167, 10.1097/BOR.0000000000000683.
Zhang, M., Hu, G., Shao, N., Qin, Y., Chen, Q., Wang, Y., Zhou, P., Cai, B., Thioredoxin-interacting protein (TXNIP) as a target for Alzheimer's disease: flavonoids and phenols. Inflammopharmacology 29 (2021), 1317–1329, 10.1007/s10787-021-00861-4.
Li, X.-F., Shen, W.-W., Sun, Y.-Y., Li, W.-X., Sun, Z.-H., Liu, Y.-H., Zhang, L., Huang, C., Meng, X.-M., Li, J., MicroRNA-20a negatively regulates expression of NLRP3-inflammasome by targeting TXNIP in adjuvant-induced arthritis fibroblast-like synoviocytes. Jt. bone spine 83 (2016), 695–700, 10.1016/j.jbspin.2015.10.007.
Lal, R., Dhaliwal, J., Dhaliwal, N., Dharavath, R.N., Chopra, K., Activation of the Nrf2/HO-1 signaling pathway by dimethyl fumarate ameliorates complete Freund's adjuvant-induced arthritis in rats. Eur. J. Pharmacol., 899, 2021, 174044, 10.1016/j.ejphar.2021.174044.
Wang, K., Lv, Q., Miao, Y.-M., Qiao, S.-M., Dai, Y., Wei, Z.-F., Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR/Nrf2/NQO1 pathway. Biochem. Pharmacol. 155 (2018), 494–509, 10.1016/j.bcp.2018.07.039.
Chen, Z., Zhong, H., Wei, J., Lin, S., Zong, Z., Gong, F., Huang, X., Sun, J., Li, P., Lin, H., et al. Inhibition of Nrf2/HO-1 signaling leads to increased activation of the NLRP3 inflammasome in osteoarthritis. Arthritis Res. Ther., 21, 2019, 300, 10.1186/s13075-019-2085-6.
Tastan, B., Arioz, B.I., Tufekci, K.U., Tarakcioglu, E., Gonul, C.P., Genc, K., Genc, S., Dimethyl fumarate alleviates NLRP3 inflammasome activation in microglia and sickness behavior in LPS-challenged mice. Front. Immunol., 12, 2021, 737065, 10.3389/fimmu.2021.737065.
Freigang, S., Ampenberger, F., Spohn, G., Heer, S., Shamshiev, A.T., Kisielow, J., Hersberger, M., Yamamoto, M., Bachmann, M.F., Kopf, M., Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur. J. Immunol. 41 (2011), 2040–2051, 10.1002/eji.201041316.
Zhao, C., Gillette, D.D., Li, X., Zhang, Z., Wen, H., Nuclear factor E2-related factor-2 (Nrf2) is required for NLRP3 and AIM2 inflammasome activation. J. Biol. Chem. 289 (2014), 17020–17029, 10.1074/jbc.M114.563114.
Zhao, J., Jiang, P., Guo, S., Schrodi, S.J., He, D., Apoptosis, autophagy, NETosis, necroptosis, and pyroptosis mediated programmed cell death as targets for innovative therapy in rheumatoid arthritis. Front. Immunol., 12, 2021, 809806, 10.3389/fimmu.2021.809806.
Akaike, A., Banno, Y., Osawa, Y., Oshita, H., Fushimi, K., Kodama, H., Shimizu, K., Synergistic induction of apoptosis of rheumatoid arthritis synovial cells by H(2)O(2) and N-acetyl-leucyl-leucyl-norleucinal. J. Orthop. Sci. 8 (2003), 346–351, 10.1007/s10776-003-0645-8.
Liu, H., Eksarko, P., Temkin, V., Haines, G.K., Perlman, H., Koch, A.E., Thimmapaya, B., Pope, R.M., Mcl-1 is essential for the survival of synovial fibroblasts in rheumatoid arthritis. J. Immunol. 175 (2005), 8337–8345, 10.4049/jimmunol.175.12.8337.
Kabala, P.A., Angiolilli, C., Yeremenko, N., Grabiec, A.M., Giovannone, B., Pots, D., Radstake, T.R., Baeten, D., Reedquist, K.A., Endoplasmic reticulum stress cooperates with Toll-like receptor ligation in driving activation of rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Res. Ther., 19, 2017, 207, 10.1186/s13075-017-1386-x.
Rajasekhar, M., Olsson, A.M., Steel, K.J.A., Georgouli, M., Ranasinghe, U., Brender Read, C., Frederiksen, K.S., Taams, L.S., MicroRNA-155 contributes to enhanced resistance to apoptosis in monocytes from patients with rheumatoid arthritis. J. Autoimmun. 79 (2017), 53–62, 10.1016/j.jaut.2017.01.002.
Perlman, H., Pagliari, L.J., Georganas, C., Mano, T., Walsh, K., Pope, R.M., FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J. Exp. Med. 190 (1999), 1679–1688, 10.1084/jem.190.11.1679.
Wu, S., Lu, H., Bai, Y., Nrf2 in cancers: a double-edged sword. Cancer Med. 8 (2019), 2252–2267, 10.1002/cam4.2101.
Telfer, J.F., Brock, J.H., Proinflammatory cytokines increase iron uptake into human monocytes and synovial fibroblasts from patients with rheumatoid arthritis. Med. Sci. Mon. Int. Med. J. Exp. Clin. Res. 10 (2004), BR91–B95.
Chen, X., Yu, C., Kang, R., Tang, D., Iron metabolism in ferroptosis. Front. Cell Dev. Biol., 8, 2020, 590226, 10.3389/fcell.2020.590226.
Stockwell, B.R., Friedmann Angeli, J.P., Bayir, H., Bush, A.I., Conrad, M., Dixon, S.J., Fulda, S., Gascón, S., Hatzios, S.K., Kagan, V.E., et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171 (2017), 273–285, 10.1016/j.cell.2017.09.021.
Forcina, G.C., Pope, L., Murray, M., Dong, W., Abu-Remaileh, M., Bertozzi, C.R., Dixon, S.J., Ferroptosis regulation by the NGLY1/NFE2L1 pathway. Proc. Natl. Acad. Sci. USA, 2022, 119, 10.1073/pnas.2118646119.
Alam, J., Stewart, D., Touchard, C., Boinapally, S., Choi, A.M., Cook, J.L., Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 274 (1999), 26071–26078, 10.1074/jbc.274.37.26071.
Koorts, A.M., Viljoen, M., Ferritin and ferritin isoforms I: structure-function relationships, synthesis, degradation and secretion. Arch. Physiol. Biochem. 113 (2007), 30–54, 10.1080/13813450701318583.
Zhao, T., Yang, Q., Xi, Y., Xie, Z., Shen, J., Li, Z., Li, Z., Qin, D., Ferroptosis in rheumatoid arthritis: a potential therapeutic strategy. Front. Immunol., 13, 2022, 779585, 10.3389/fimmu.2022.779585.
Xiao, W., Beibei, F., Guangsi, S., Yu, J., Wen, Z., Xi, H., Youjia, X., Iron overload increases osteoclastogenesis and aggravates the effects of ovariectomy on bone mass. J. Endocrinol. 226 (2015), 121–134, 10.1530/JOE-14-0657.
Vomero, M., Barbati, C., Colasanti, T., Perricone, C., Novelli, L., Ceccarelli, F., Spinelli, F.R., Di Franco, M., Conti, F., Valesini, G., et al. Autophagy and rheumatoid arthritis: current knowledges and future perspectives. Front. Immunol., 9, 2018, 1577, 10.3389/fimmu.2018.01577.
Kurien, B.T., Hensley, K., Bachmann, M., Scofield, R.H., Oxidatively modified autoantigens in autoimmune diseases. Free Radic. Biol. Med. 41 (2006), 549–556, 10.1016/j.freeradbiomed.2006.05.020.
Ireland, J.M., Unanue, E.R., Processing of proteins in autophagy vesicles of antigen-presenting cells generates citrullinated peptides recognized by the immune system. Autophagy 8 (2012), 429–430, 10.4161/auto.19261.
Chen, Y.-M., Chang, C.-Y., Chen, H.-H., Hsieh, C.-W., Tang, K.-T., Yang, M.-C., Lan, J.-L., Chen, D.-Y., Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy. Arthritis Res. Ther., 20, 2018, 268, 10.1186/s13075-018-1763-0.
Jain, A., Lamark, T., Sjøttem, E., Larsen, K.B., Awuh, J.A., Øvervatn, A., McMahon, M., Hayes, J.D., Johansen, T., p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J. Biol. Chem. 285 (2010), 22576–22591, 10.1074/jbc.M110.118976.
Copple, I.M., Lister, A., Obeng, A.D., Kitteringham, N.R., Jenkins, R.E., Layfield, R., Foster, B.J., Goldring, C.E., Park, B.K., Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. J. Biol. Chem. 285 (2010), 16782–16788, 10.1074/jbc.M109.096545.
Liu, W.J., Ye, L., Huang, W.F., Guo, L.J., Xu, Z.G., Wu, H.L., Yang, C., Liu, H.F., p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation. Cell. Mol. Biol. Lett., 21, 2016, 29, 10.1186/s11658-016-0031-z.
Wu, X., Sun, R., Wang, H., Yang, B., Wang, F., Xu, H., Chen, S., Zhao, R., Pi, J., Xu, Y., Enhanced p62-NRF2 feedback loop due to impaired autophagic flux contributes to arsenic-induced malignant transformation of human keratinocytes. Oxid. Med. Cell. Longev., 2019, 1038932, 10.1155/2019/1038932 2019.
Demarco, B., Danielli, S., Fischer, F.A., Bezbradica, J.S., How pyroptosis contributes to inflammation and fibroblast-macrophage cross-talk in rheumatoid arthritis. Cells, 11, 2022, 10.3390/cells11081307.
Hennig, P., Garstkiewicz, M., Grossi, S., Di Filippo, M., French, L.E., Beer, H.-D., The crosstalk between Nrf2 and inflammasomes. Int. J. Mol. Sci., 19, 2018, 10.3390/ijms19020562.
Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., Cuadrado, A., Activators and inhibitors of NRF2: a review of their potential for clinical development. Oxid. Med. Cell. Longev., 2019, 9372182, 10.1155/2019/9372182 2019.
Saha, S., Buttari, B., Panieri, E., Profumo, E., Saso, L., An overview of Nrf2 signaling pathway and its role in inflammation. Molecules, 25, 2020, 10.3390/molecules25225474.
Kim, M.-J., Jeon, J.-H., Recent advances in understanding Nrf2 agonism and its potential clinical application to metabolic and inflammatory diseases. Int. J. Mol. Sci., 2022, 23, 10.3390/ijms23052846.
Pouremamali, F., Pouremamali, A., Dadashpour, M., Soozangar, N., Jeddi, F., An update of Nrf2 activators and inhibitors in cancer prevention/promotion. Cell Commun. Signal., 20, 2022, 100, 10.1186/s12964-022-00906-3.
Poole, L.B., The basics of thiols and cysteines in redox biology and chemistry. Free Radic. Biol. Med. 80 (2015), 148–157, 10.1016/j.freeradbiomed.2014.11.013.
Schulze-Topphoff, U., Varrin-Doyer, M., Pekarek, K., Spencer, C.M., Shetty, A., Sagan, S.A., Cree, B.A.C., Sobel, R.A., Wipke, B.T., Steinman, L., et al. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc. Natl. Acad. Sci. U. S. A 113 (2016), 4777–4782, 10.1073/pnas.1603907113.
Offermanns, S., Schwaninger, M., Nutritional or pharmacological activation of HCA(2) ameliorates neuroinflammation. Trends Mol. Med. 21 (2015), 245–255, 10.1016/j.molmed.2015.02.002.
Hayashi, G., Jasoliya, M., Sahdeo, S., Saccà, F., Pane, C., Filla, A., Marsili, A., Puorro, G., Lanzillo, R., Brescia Morra, V.; et al. Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans. Hum. Mol. Genet. 26 (2017), 2864–2873, 10.1093/hmg/ddx167.
Blewett, M.M., Xie, J., Zaro, B.W., Backus, K.M., Altman, A., Teijaro, J.R., Cravatt, B.F., Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells. Sci. Signal., 9, 2016, rs10, 10.1126/scisignal.aaf7694.
Sulaimani, J., Cluxton, D., Clowry, J., Petrasca, A., Molloy, O.E., Moran, B., Sweeney, C.M., Malara, A., McNicholas, N., McGuigan, C., et al. Dimethyl fumarate modulates the Treg-Th17 cell axis in patients with psoriasis. Br. J. Dermatol. 184 (2021), 495–503, 10.1111/bjd.19229.
Mills, E.A., Ogrodnik, M.A., Plave, A., Mao-Draayer, Y., Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front. Neurol., 9, 2018, 5, 10.3389/fneur.2018.00005.
Montes Diaz, G., Hupperts, R., Fraussen, J., Somers, V., Dimethyl fumarate treatment in multiple sclerosis: recent advances in clinical and immunological studies. Autoimmun. Rev. 17 (2018), 1240–1250, 10.1016/j.autrev.2018.07.001.
Schett, G., Rheumatoid arthritis and multiple sclerosis: direful siblings, different strategies. FEBS Lett. 585 (2011), 3601–3602, 10.1016/j.febslet.2011.10.030.
Moon, S.-J., Jhun, J., Ryu, J., Kwon, J.Y., Kim, S.-Y., Jung, K., Cho, M.-L., Min, J.-K., The anti-arthritis effect of sulforaphane, an activator of Nrf2, is associated with inhibition of both B cell differentiation and the production of inflammatory cytokines. PLoS One, 16, 2021, e0245986, 10.1371/journal.pone.0245986.
Fragoulis, A., Laufs, J., Müller, S., Soppa, U., Siegl, S., Reiss, L.K., Tohidnezhad, M., Rosen, C., Tenbrock, K., Varoga, D., et al. Sulforaphane has opposing effects on TNF-alpha stimulated and unstimulated synoviocytes. Arthritis Res. Ther., 14, 2012, R220, 10.1186/ar4059.
Kim, H.-J., Barajas, B., Wang, M., Nel, A.E., Nrf2 activation by sulforaphane restores the age-related decrease of T(H)1 immunity: role of dendritic cells. J. Allergy Clin. Immunol. 121 (2008), 1255–1261, 10.1016/j.jaci.2008.01.016 e7.
Geisel, J., Brück, J., Glocova, I., Dengler, K., Sinnberg, T., Rothfuss, O., Walter, M., Schulze-Osthoff, K., Röcken, M., Ghoreschi, K., Sulforaphane protects from T cell-mediated autoimmune disease by inhibition of IL-23 and IL-12 in dendritic cells. J. Immunol. 192 (2014), 3530–3539, 10.4049/jimmunol.1300556.
Chartoumpekis, D.V., Fu, C.-Y., Ziros, P.G., Sykiotis, G.P., Patent review (2017-2020) of the keap1/nrf2 pathway using PatSeer pro: focus on autoimmune diseases. Antioxidants, 9, 2020, 10.3390/antiox9111138.
Nangaku, M., Kanda, H., Takama, H., Ichikawa, T., Hase, H., Akizawa, T., Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study). Kidney Int. reports 5 (2020), 879–890, 10.1016/j.ekir.2020.03.030.
Saeed, H., Mateen, S., Moin, S., Khan, A.Q., Owais, M., Cardiac glycoside digoxin ameliorates pro-inflammatory cytokines in PBMCs of rheumatoid arthritis patients in vitro. Int. Immunopharm., 82, 2020, 106331, 10.1016/j.intimp.2020.106331.
Gall, E.P., The safety of treating rheumatoid arthritis with aspirin. JAMA 247 (1982), 63–64.
Jian, Z., Tang, L., Yi, X., Liu, B., Zhang, Q., Zhu, G., Wang, G., Gao, T., Li, C., Aspirin induces Nrf2-mediated transcriptional activation of haem oxygenase-1 in protection of human melanocytes from H2 O2 -induced oxidative stress. J. Cell Mol. Med. 20 (2016), 1307–1318, 10.1111/jcmm.12812.
Wei, W., Shurui, C., Zipeng, Z., Hongliang, D., Hongyu, W., Yuanlong, L., Kang, Z., Zhaoliang, S., Yue, G., Chang, L., et al. Aspirin suppresses neuronal apoptosis, reduces tissue inflammation, and restrains astrocyte activation by activating the Nrf2/HO-1 signaling pathway. Neuroreport 29 (2018), 524–531, 10.1097/WNR.0000000000000969.
Baber, N., Halliday, L.D., van den Heuvel, W.J., Walker, R.W., Sibeon, R., Keenan, J.P., Littler, T., Orme, M.L., Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics, and platelet studies in responders and nonresponders. Ann. Rheum. Dis. 38 (1979), 128–136, 10.1136/ard.38.2.128.
Eisenstein, A., Hilliard, B.K., Pope, S.D., Zhang, C., Taskar, P., Waizman, D.A., Israni-Winger, K., Tian, H., Luan, H.H., Wang, A., Activation of the transcription factor NRF2 mediates the anti-inflammatory properties of a subset of over-the-counter and prescription NSAIDs. Immunity 55 (2022), 1082–1095, 10.1016/j.immuni.2022.04.015 e5.
Yoshinaga, N., Arimura, N., Otsuka, H., Kawahara, K.-I., Hashiguchi, T., Maruyama, I., Sakamoto, T., NSAIDs inhibit neovascularization of choroid through HO-1-dependent pathway. Lab. Invest. 91 (2011), 1277–1290, 10.1038/labinvest.2011.101.
Fidahic, M., Jelicic Kadic, A., Radic, M., Puljak, L., Celecoxib for rheumatoid arthritis. Cochrane Database Syst. Rev., 6, 2017, CD012095, 10.1002/14651858.CD012095.pub2.
Al-Rashed, F., Calay, D., Lang, M., Thornton, C.C., Bauer, A., Kiprianos, A., Haskard, D.O., Seneviratne, A., Boyle, J.J., Schönthal, A.H., et al. Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling. Sci. Rep., 8, 2018, 6271, 10.1038/s41598-018-24548-z.
Cutolo, M., Paolino, S., Gotelli, E., Glucocorticoids in rheumatoid arthritis still on first line: the reasons. Expet Rev. Clin. Immunol. 17 (2021), 417–420, 10.1080/1744666X.2021.1903319.
Biagiotti, S., Menotta, M., Orazi, S., Spapperi, C., Brundu, S., Fraternale, A., Bianchi, M., Rossi, L., Chessa, L., Magnani, M., Dexamethasone improves redox state in ataxia telangiectasia cells by promoting an NRF2-mediated antioxidant response. FEBS J. 283 (2016), 3962–3978, 10.1111/febs.13901.
Li, B., Li, R., Xie, X., Song, X., Zhang, J., Wang, Y., Guo, L., [Anti-oxidative effects of dexamethasone on mice with experimental autoimmune encephalomyelitis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 29 (2013), 1155–1158.
Alam, M.M., Okazaki, K., Nguyen, L.T.T., Ota, N., Kitamura, H., Murakami, S., Shima, H., Igarashi, K., Sekine, H., Motohashi, H., Glucocorticoid receptor signaling represses the antioxidant response by inhibiting histone acetylation mediated by the transcriptional activator NRF2. J. Biol. Chem. 292 (2017), 7519–7530, 10.1074/jbc.M116.773960.
Pels, R., Sterry, W., Lademann, J., Clobetasol propionate–where, when, why?. Drugs Today 44 (2008), 547–557, 10.1358/dot.2008.44.7.1122221.
Choi, E.-J., Jung, B.-J., Lee, S.-H., Yoo, H.-S., Shin, E.-A., Ko, H.-J., Chang, S., Kim, S.-Y., Jeon, S.-M., A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer. Oncogene 36 (2017), 5285–5295, 10.1038/onc.2017.153.
Chikanza, I.C., Kozaci, D.L., Corticosteroid resistance in rheumatoid arthritis: molecular and cellular perspectives. Rheumatology (Oxford) 43 (2004), 1337–1345, 10.1093/rheumatology/keh333.
Kratschmar, D.V., Calabrese, D., Walsh, J., Lister, A., Birk, J., Appenzeller-Herzog, C., Moulin, P., Goldring, C.E., Odermatt, A., Suppression of the Nrf2-dependent antioxidant response by glucocorticoids and 11β-HSD1-mediated glucocorticoid activation in hepatic cells. PLoS One, 7, 2012, e36774, 10.1371/journal.pone.0036774.
Zimmerman, M.C., Clemens, D.L., Duryee, M.J., Sarmiento, C., Chiou, A., Hunter, C.D., Tian, J., Klassen, L.W., O'Dell, J.R., Thiele, G.M., et al. Direct antioxidant properties of methotrexate: inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging. Redox Biol. 13 (2017), 588–593, 10.1016/j.redox.2017.07.018.
Dogru, A., Nazıroglu, M., Cig, B., Modulator role of infliximab and methotrexate through the transient receptor potential melastatin 2 (TRPM2) channel in neutrophils of patients with rheumatoid arthritis: a pilot study. Arch. Med. Sci. 15 (2019), 1415–1424, 10.5114/aoms.2018.79485.
Dar, A.A., Fehaid, A., Alkhatani, S., Alarifi, S., Alqahtani, W.S., Albasher, G., Almeer, R., Alfarraj, S., Moneim, A.A., The protective role of luteolin against the methotrexate-induced hepato-renal toxicity via its antioxidative, anti-inflammatory, and anti-apoptotic effects in rats. Hum. Exp. Toxicol. 40 (2021), 1194–1207, 10.1177/0960327121991905.
Breedveld, F.C., Dayer, J.M., Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 59 (2000), 841–849, 10.1136/ard.59.11.841.
Moon, S.-J., Kim, E.-K., Jhun, J.Y., Lee, H.J., Lee, W.S., Park, S.-H., Cho, M.-L., Min, J.-K., The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1. J. Transl. Med., 15, 2017, 31, 10.1186/s12967-017-1131-x.
Roder, C., Thomson, M.J. Auranofin, Repurposing an old drug for a golden new age. Drugs R 15 (2015), 13–20, 10.1007/s40268-015-0083-y.
Kataoka, K., Handa, H., Nishizawa, M., Induction of cellular antioxidative stress genes through heterodimeric transcription factor Nrf2/small Maf by antirheumatic gold(I) compounds. J. Biol. Chem. 276 (2001), 34074–34081, 10.1074/jbc.M105383200.
Kim, N.-H., Oh, M.-K., Park, H.J., Kim, I.-S. Auranofin, A gold(I)-containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation. J. Pharmacol. Sci. 113 (2010), 246–254, 10.1254/jphs.09330fp.
Dunigan, K., Li, Q., Li, R., Locy, M.L., Wall, S., Tipple, T.E., The thioredoxin reductase inhibitor auranofin induces heme oxygenase-1 in lung epithelial cells via Nrf2-dependent mechanisms. Am. J. Physiol. Lung Cell Mol. Physiol. 315 (2018), L545–L552, 10.1152/ajplung.00214.2018.
Lis, K., Kuzawińska, O., Bałkowiec-Iskra, E., Tumor necrosis factor inhibitors - state of knowledge. Arch. Med. Sci. 10 (2014), 1175–1185, 10.5114/aoms.2014.47827.
Namakkal-Soorappan, R., TNF-alpha is not a miscreant: a hero for basal nrf2-antioxidant signaling. React. Oxyg. species (Apex, N.C.) 4 (2017), 298–302, 10.20455/ros.2017.849.
Hu, S., Lin, Y., Tong, C., Huang, H., Yi, O., Dai, Z., Su, Z., Liu, B., Cai, X., A pH-Driven indomethacin-loaded nanomedicine for effective rheumatoid arthritis therapy by combining with photothermal therapy. J. Drug Target. 30 (2022), 737–752, 10.1080/1061186X.2022.2053539.
Redondo, A., Chamorro, P.A.F., Riego, G., Leánez, S., Pol, O., Treatment with sulforaphane produces antinociception and improves morphine effects during inflammatory pain in mice. J. Pharmacol. Exp. Therapeut. 363 (2017), 293–302, 10.1124/jpet.117.244376.
Buchbinder, R., Hall, S., Sambrook, P.N., Champion, G.D., Harkness, A., Lewis, D., Littlejohn, G.O., Miller, M.H., Ryan, P.F., Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J. Rheumatol. 20 (1993), 639–644.
Sparks, J.A., Barbhaiya, M., Karlson, E.W., Ritter, S.Y., Raychaudhuri, S., Corrigan, C.C., Lu, F., Selhub, J., Chasman, D.I., Paynter, N.P., et al. Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: rationale and design of the cardiovascular inflammation reduction trial-adverse events (CIRT-AE) study. Semin. Arthritis Rheum. 47 (2017), 133–142, 10.1016/j.semarthrit.2017.02.003.
Dayoub, R., Vogel, A., Schuett, J., Lupke, M., Spieker, S.M., Kettern, N., Hildt, E., Melter, M., Weiss, T.S., Nrf2 activates augmenter of liver regeneration (ALR) via antioxidant response element and links oxidative stress to liver regeneration. Mol. Med. 19 (2013), 237–244, 10.2119/molmed.2013.00027.
Maher, J.M., Dieter, M.Z., Aleksunes, L.M., Slitt, A.L., Guo, G., Tanaka, Y., Scheffer, G.L., Chan, J.Y., Manautou, J.E., Chen, Y., et al. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology 46 (2007), 1597–1610, 10.1002/hep.21831.
Imenshahidi, M., Hosseinzadeh, H., Berberis vulgaris and berberine: an update review. Phytother Res. 30 (2016), 1745–1764, 10.1002/ptr.5693.
Hassanein, E.H.M., Shalkami, A.-G.S., Khalaf, M.M., Mohamed, W.R., Hemeida, R.A.M., The impact of Keap1/Nrf2, P38MAPK/NF-κB and Bax/Bcl2/caspase-3 signaling pathways in the protective effects of berberine against methotrexate-induced nephrotoxicity. Biomed. Pharmacother. 109 (2019), 47–56, 10.1016/j.biopha.2018.10.088.
Thangapandiyan, S., Ramesh, M., Miltonprabu, S., Hema, T., Jothi, G.B., Nandhini, V., Sulforaphane potentially attenuates arsenic-induced nephrotoxicity via the PI3K/Akt/Nrf2 pathway in albino Wistar rats. Environ. Sci. Pollut. Res. Int. 26 (2019), 12247–12263, 10.1007/s11356-019-04502-w.
Márki-Zay, J.; Tauberné Jakab, K.; Szerémy, P.; Krajcsi, P. MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin. Exp. Rheumatol. 31, 779–787.
Atisha-Fregoso, Y., Lima, G., Pascual-Ramos, V., Baños-Peláez, M., Fragoso-Loyo, H., Jakez-Ocampo, J., Contreras-Yáñez, I., Llorente, L., Rheumatoid arthritis disease activity is determinant for ABCB1 and ABCG2 drug-efflux transporters function. PLoS One, 11, 2016, e0159556, 10.1371/journal.pone.0159556.
Adachi, T., Nakagawa, H., Chung, I., Hagiya, Y., Hoshijima, K., Noguchi, N., Kuo, M.T., Ishikawa, T., Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J. Exp. Therapeut. Oncol. 6 (2007), 335–348.
Gorczyca, L., Aleksunes, L.M., Transcription factor-mediated regulation of the BCRP/ABCG2 efflux transporter: a review across tissues and species. Expet Opin. Drug Metabol. Toxicol. 16 (2020), 239–253, 10.1080/17425255.2020.1732348.
Hira, D., Terada, T., BCRP/ABCG2 and high-alert medications: biochemical, pharmacokinetic, pharmacogenetic, and clinical implications. Biochem. Pharmacol. 147 (2018), 201–210, 10.1016/j.bcp.2017.10.004.
Saib, S., Delavenne, X., Inflammation induces changes in the functional expression of P-gp, BCRP, and MRP2: an overview of different models and consequences for drug disposition. Pharmaceutics, 13, 2021, 10.3390/pharmaceutics13101544.
Procko, E., Gaudet, R., Antigen processing and presentation: TAPping into ABC transporters. Curr. Opin. Immunol. 21 (2009), 84–91, 10.1016/j.coi.2009.02.003.
